SNPMiner Trials (Home Page)
Report for SNP rs10766197
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Effects of Fat-soluble Vitamins Supplementation in Early Life on Common Complications and Neural Development in Very Low Birth Weight Infants
Vitamins A, D, and E play important roles in humans, such as vision function, immune function, bone metabolism, cell growth and differentiation and oxidation resistance. Deficiencies in these vitamins will result in a high prevalence of cardiovascular disease, infection, bone diseases, etc. Preterm infants, especially very low birth weight infants, are at risk of vitamin deficiency. Intravenous perfusion is the most common and widely used method to supply vitamins for the specific population in early life. However, the current dose of vitamin supplied by intravenous perfusion whether can meet the need of growth and development is not sure and the appropriate dose for preterm infants is still uncertain. The purpose of this study is to investigate whether current dose of fat-soluble vitamin supplementation is enough for very low birth weight infants, the safety of high dose of fat-soluble vitamin supplementation, and compare the differences of prevalence of common complications, such as bronchopulmonary dysplasia, patent ductus arteriosus, sepsis, anemia, and neural development between these two groups.
NCT03876704 Vitamin A Deficiency Vitamin D Deficiency Vitamin E Deficiency Very Low Birth Weight Infants Bronchopulmonary Dysplasia Anemia Sepsis Drug: High dose of fat-Soluble Vitamin Drug: Conventional dose of fat-Soluble Vitamin MeSH:Bronchopulmonary Dysplasia Night Blindness Vitamin D Deficiency Vitamin A Deficiency Vitamin E Deficiency Body Weight Birth Weight
HPO:Low levels of vitamin A Low levels of vitamin D Low levels of vitamin E Nyctalopia
Association of rs4588 polymorphism in vitamin D receptor gene and rs10766197 polymorphism in the cytochrome P450 family 2 subfamily R member 1 gene with baseline level of vitamin D and change in vitamin D level after 4~6 weeks' supplementation.
Primary Outcomes
Description: Change from baseline level of vitamin A, vitamin D, and vitamin E at 4~6 weeks
Measure: Vitamin levels Time: within 72 hours after birth, 4~6 weeks oldSecondary Outcomes
Description: The prevalence of bronchopulmonary dysplasia, patent ductus arteriosus, sepsis, anemia, intracranial hemorrhage, extrauterine growth retardation, etc.
Measure: Complications Time: corrected age of 36 weeksDescription: White matter disease of the preterm infant, was semiquantitatively assessed from MRI at term-equivalent age based on an established scoring method.
Measure: Neural development Time: corrected age of 40 weeksDescription: Association of rs4588 polymorphism in vitamin D receptor gene and rs10766197 polymorphism in the cytochrome P450 family 2 subfamily R member 1 gene with baseline level of vitamin D and change in vitamin D level after 4~6 weeks' supplementation
Measure: Gene polymorphism in vitamin deficiency preterm infants Time: within 72 hours after birth, 4~6 weeks old